Publisher
Springer International Publishing
Reference48 articles.
1. Wu Z, Wang K, Yang Z et al (2020) A novel androgen receptor antagonist JJ-450 inhibits enzalutamide-resistant mutant ARF876L nuclear import and function. Prostate 80:319–328
2. Jimenez-Vacas JM, Herrero-Aguayo V, Montero-Hidalgo AJ. et al. Dysregulation of the splicing machinery is directly associated to aggressiveness of prostate cancer. EBioMedicine 51:102547
3. Twillie DA, Eisenberger MA, Carducci MA, Hseih WS, Kim WY, Simons JW (1995) Interleukin-6: a candidate mediator of human prostate cancer morbidity. Urology 45:542–549
4. Keller ET, Chang C, Ershler WB (1996) Inhibition of Nfkappa B activity through maintenance of IkappaBalpha levels contributes to dihydrotestosterone-mediated repression of the interleukin-6 promoter. J Biol Chem 271:26265–26267
5. Park JI, Lee MG, Cho K et al (2003) Transforming growth factor-beta1 activates interleukin-6 expression in prostate cancer through the synergistic collaboration of the Smad2, p38-NF-kappaB, JNK, and Ras signaling pathways. Oncogene 22:4314–4332
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献